PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsZurex Pharma
Zurex Pharma
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
ZuragardFenofibrate2019-04-262024-2033
Hypercholesterolemia
,
Coronary artery disease
,
Dyslipidemias
,
Hypertriglyceridemia
,
Hyperlipoproteinemias
,
Periodontal diseases
,
Infectious skin diseases
,
Gram-negative bacterial infections
,
Oral candidiasis
,
Gram-positive bacterial infections
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Fenofibrate
surgical wound infection
Bevifimod
neoplasms
,
asthma
,
pancreatic neoplasms
,
adenocarcinoma
,
prostatic neoplasms
,
psoriasis
,
rheumatoid arthritis
,
juvenile arthritis
,
fever
,
arthralgia
,
exanthema
,
hiv infections
Riboprine
surgical wound infection
Crystalloid
healthy volunteers/patients
,
osteoarthritis
,
major depressive disorder
,
prostatic hyperplasia
,
skin aging
,
carpal tunnel syndrome
,
premature ejaculation
,
neuralgia
,
hyperalgesia
,
cicatrix
,
torticollis
,
depression
,
systemic lupus erythematosus
,
muscle spasticity
,
stroke
,
urinary incontinence
,
cerebral palsy
,
migraine disorders
,
multiple sclerosis
,
neurogenic urinary bladder
,
overactive urinary bladder
Zuraprep
surgical wound infection
Chloraprep
surgical wound infection
Corsodyl
bacteremia
,
sepsis
,
pneumonia
,
urinary tract infections
,
clostridium infections
,
infections
,
communicable diseases
,
surgical wound infection
,
cross infection
,
postoperative complications
,
ventilator-associated pneumonia
,
oral hygiene
,
staphylococcal infections
,
methicillin-resistant staphylococcus aureus
,
infectious skin diseases
,
soft tissue infections
,
asymptomatic infections
,
reinfection
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use